Related Experiment Videos
[Oral vaccination with live attenuated rotavirus]
H Escobar Castro1, M Perdomo Giraldi, A Tamáriz-Martel Moreno
1Unidad de Gastroenterología, Hospital Ramón y Cajal, Madrid.
Anales Espanoles De Pediatria
|June 1, 1988
Summary
This study found that while the rotavirus vaccine (RIT 4237) induced significant seroconversion in children, it offered limited clinical protection against gastroenteritis. Seroconversion alone is insufficient to measure vaccine efficacy.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Rotavirus is a leading cause of acute gastroenteritis in children worldwide.
- Vaccine development aims to prevent rotavirus infections and reduce disease burden.
Purpose of the Study:
- To evaluate the serological response and clinical protection offered by a single dose of RIT 4237 live attenuated bovine rotavirus vaccine.
- To assess the correlation between seroconversion and clinical efficacy in children aged 6-18 months.
Main Methods:
- A randomized, double-blind trial involving 103 children aged 6 to 18 months.
- Administration of a single dose of RIT 4237 vaccine or placebo.
- Serological response assessed by enzyme-linked immunoabsorbent assay (ELISA) for seroconversion.
Main Results:
- Significantly higher seroconversion rates were observed in the vaccine group compared to the placebo group (p < 0.0001).
- The clinical protection rate against acute gastroenteritis was low in the study population.
- A discrepancy was noted between high seroconversion and low clinical protection.
Conclusions:
- Seroconversion following rotavirus vaccination does not solely guarantee clinical protection.
- Further research is needed to establish robust correlates of protection for rotavirus vaccines.
- Current measures may need refinement to accurately reflect vaccine effectiveness in preventing rotavirus gastroenteritis.